 |
| << Back |
| Dyax Corp. to Present at the Cowen and Company Health Care Conference |
CAMBRIDGE, Mass., Feb 24, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Cowen and Company 30th Annual Health Care Conference, being held March 8-11th at the Marriott Copley Place in Boston, MA. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) (ecallantide) and clinical development programs. The Dyax presentation is scheduled for Wednesday, March 10th at 8:45 AM (ET). The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at http://www.dyax.com. The 35-minute presentation will also be available on the Dyax website for a limited period of time following the conference. About Dyax Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company utilizes its proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit http://www.dyax.com. SOURCE: Dyax Corp. Dyax Corp. |
|